School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada
Faculty of Pharmacy and Charles Perkins Centre, University of Sydney Faculty of Health Sciences, The University of Sydney, New South Wales, Australia.
BMJ Open. 2023 Mar 21;13(3):e068221. doi: 10.1136/bmjopen-2022-068221.
To understand how the experiences and views of trial participants, trial investigators and others connected to clinical trial research relate to whether researchers have a duty to participants to publicly report research findings.
Qualitative interview study.
Semistructured interviews held in person or by telephone between March 2019 and April 2021 with participants in the Canadian provinces of Alberta, British Columbia and Ontario.
34 participants, including 10 clinical trial participants, 17 clinical trial investigators, 1 clinical research coordinator, 3 research administrators and 3 research ethics board members.
We conducted a thematic analysis, including qualitative coding of interview transcripts and identification of key themes.
Key themes identified through qualitative coding of interview data.
Most clinical trial participants felt that reporting clinical trial results is important. Accounts of trial participants suggest their contributions are part of a reciprocal relationship involving the expectation that research will advance medical knowledge. Similarly, comments from trial investigators suggest that reporting trial results is part of reciprocity with trial participants and is a necessary part of honouring informed consent. Accounts of trial investigators suggest that when drug trials are not reported, this may undermine informed consent in subsequent trials by withholding information on harms or efficacy relevant to informed decisions on whether to conduct or enroll in future trials of similar drugs.
The views of trial participants, trial investigators and others connected to clinical trial research in Canada suggest that researchers have an obligation to participants to publicly report clinical trial results and that reporting results is necessary for honouring informed consent.
了解临床试验参与者、研究者和其他与临床试验研究相关人员的经验和观点如何影响研究人员是否有责任向参与者公开报告研究结果。
定性访谈研究。
2019 年 3 月至 2021 年 4 月期间,在加拿大艾伯塔省、不列颠哥伦比亚省和安大略省进行了半结构化访谈,受访者包括 10 名临床试验参与者、17 名临床试验研究者、1 名临床研究协调员、3 名研究管理人员和 3 名研究伦理委员会成员。
34 名参与者,包括 10 名临床试验参与者、17 名临床试验研究者、1 名临床研究协调员、3 名研究管理人员和 3 名研究伦理委员会成员。
我们进行了主题分析,包括对访谈记录进行定性编码和确定关键主题。
通过对访谈数据的定性编码确定的关键主题。
大多数临床试验参与者认为报告临床试验结果很重要。参与者的描述表明,他们的贡献是一种互惠关系的一部分,期望研究能推进医学知识。同样,临床试验研究者的评论表明,报告试验结果是与试验参与者互惠的一部分,也是尊重知情同意的必要组成部分。临床试验研究者的描述表明,当药物试验未报告时,这可能会通过隐瞒与知情决策相关的危害或疗效信息,从而破坏后续试验中的知情同意,这些信息对于决定是否进行或参与类似药物的未来试验至关重要。
加拿大临床试验参与者、研究者和其他与临床试验研究相关人员的观点表明,研究人员有向参与者公开报告临床试验结果的义务,报告结果是尊重知情同意的必要条件。